Pharma Stock Roundup: LLY's Zepbound Success, FDA Updates for MRK, JNJ

Zacks12-06

This week, Eli Lilly’s LLY popular obesity drug, Zepbound showed better weight loss than Novo Nordisk’s Wegovy in a head-to-head study. The FDA granted Breakthrough Therapy designation to Merck’s MRK ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2489231752?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kHYuj_GDhroF7BEQsCcsVA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887","is_english":true,"pubTime":"2024-12-06 21:11","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2489231752","market":"us","top_or_hot":-1,"title":"Pharma Stock Roundup: LLY's Zepbound Success, FDA Updates for MRK, JNJ","media":"Zacks","content":"<div>\n<p>This week, Eli Lilly’s LLY popular obesity drug, Zepbound showed better weight loss than Novo Nordisk’s Wegovy in a head-to-head study. The FDA granted Breakthrough Therapy designation to Merck’s MRK ...</p>\n\n<a href=\"https://finance.yahoo.com/news/pharma-stock-roundup-llys-zepbound-131100794.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharma Stock Roundup: LLY's Zepbound Success, FDA Updates for MRK, JNJ</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharma Stock Roundup: LLY's Zepbound Success, FDA Updates for MRK, JNJ\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-06 21:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/pharma-stock-roundup-llys-zepbound-131100794.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>This week, Eli Lilly’s LLY popular obesity drug, Zepbound showed better weight loss than Novo Nordisk’s Wegovy in a head-to-head study. The FDA granted Breakthrough Therapy designation to Merck’s MRK ...</p>\n\n<a href=\"https://finance.yahoo.com/news/pharma-stock-roundup-llys-zepbound-131100794.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RHHBY","symbol_name":"罗氏控股","start_time":0,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-llys-zepbound-131100794.html","article_id":"2489231752","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kHYuj_GDhroF7BEQsCcsVA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489231752","pubTimestamp":1733490660,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"This week, Eli Lilly’s LLY popular obesity drug, Zepbound showed better weight loss than Novo Nordisk’s Wegovy in a head-to-head study. The FDA granted Breakthrough Therapy designation to Merck’s MRK candidate sacituzumab tirumotecan for a lung cancer indication and approved AstraZeneca’s AZN blockbuster cancer drug, Imfinzi for a new indication. The FDA also accepted Roche’s RHHBY supplemental filing seeking expanded use of its drug, Columvi. J&J JNJ also filed an application with the FDA, seeking approval of Tremfya for children.Here's a recap of the week’s most important stories.LLY’s Zepbound Outperforms NVO’s Wegovy in Weight Loss Study. The FDA granted approval to AstraZeneca’s Imfinzi for treating limited-stage small cell lung cancer , an aggressive form of lung cancer, in the United States. The approval was based on data from the ADRIATIC phase III study for LS-SCLC patients whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"RHHBY":"罗氏控股","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","AZN":"阿斯利康","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","03165":"华夏欧优股对冲","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU2063271972.USD":"富兰克林创新领域基金","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","MRK":"默沙东","JNJ":"强生","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","ADC":"艾格里房产","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0861579265.USD":"联博低波幅策略股票基金A","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LLY":"礼来","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC"},"translate_title":"制药股综述：LLY的Zepbound成功、FDA对MRK、JNJ的更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADC":1,"MRK":1,"RHHBY":1,"LLY":1,"JNJ":1,"AZN":1,"03165":0.6},"content_text":"This week, Eli Lilly’s LLY popular obesity drug, Zepbound showed better weight loss than Novo Nordisk’s Wegovy in a head-to-head study. The FDA granted Breakthrough Therapy designation to Merck’s MRK candidate sacituzumab tirumotecan (Sac-TMT) for a lung cancer indication and approved AstraZeneca’s AZN blockbuster cancer drug, Imfinzi for a new indication. The FDA also accepted Roche’s RHHBY supplemental filing seeking expanded use of its drug, Columvi. J&J JNJ also filed an application with the FDA, seeking approval of Tremfya for children.\nHere's a recap of the week’s most important stories.\nLLY’s Zepbound Outperforms NVO’s Wegovy in Weight Loss Study\nLilly’s obesity drug, Zepbound, showed an average weight loss of 20.2%, which was superior to 13.7% for Novo Nordisk’s Wegovy (semaglutide) in a first-ever head-to-head obesity study, SURMOUNT-5. This represents a 47% greater relative weight loss for Zepbound users compared to Wegovy. Participants given Zepbound lost an average of 50.3 lbs (22.8 kg) compared to 33.1 lbs (15.0 kg) for those taking Wegovy. Additionally, in a key secondary endpoint, 31.6% of those taking Zepbound achieved a weight loss of at least 25% of their body weight, compared to 16.1% for Wegovy users.\nIn the study, Zepbound showed superior results across the primary endpoint and all five key secondary endpoints, and its safety profile was consistent with previous studies.\nLilly announced a $3 billion expansion plan for its manufacturing facility in Wisconsin, which the company acquired in April. The investment is expected to help meet the growing demand for Mounjaro and Zepbound by expanding the company’s injectable product manufacturing network. Since 2020, Lilly has committed more than $23 billion for manufacturing capacity for Zepbound and Mounjaro in the United States and Europe\nFDA’s Breakthrough Tag to MRK’s Lung Cancer ADC\nThe FDA granted Breakthrough Therapy designation to Merck pipeline candidate, sacituzumab tirumotecan (Sac-TMT), for the treatment of certain patients with previously treated advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) with EGFR mutations. Sac-TMT is a TROP2-directed antibody drug conjugate (ADC) that Merck is developing in partnership with Chinese company, Kelun-Biotech.\nSac-TMT was recently approved in China for a breast cancer indication. Kelun-Biotech owns rights to develop, manufacture and commercialize sac-TMT in Greater China. Merck is currently developing sac-TMT as a monotherapy and in combination with Keytruda in 10 phase III studies across various solid tumors.\nFDA Approves AZN’s Imfinzi for Aggressive Lung Cancer\nThe FDA granted approval to AstraZeneca’s Imfinzi for treating limited-stage small cell lung cancer (LS-SCLC), an aggressive form of lung cancer, in the United States. The approval was based on data from the ADRIATIC phase III study for LS-SCLC patients whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. Imfinzi was also earlier granted Breakthrough Therapy Designation by the FDA for the same indication.\nImfinzi, either as a monotherapy or in combination with chemotherapy, is presently approved for stage III non-small cell lung cancer, extensive-stage SCLC, locally advanced or metastatic biliary tract cancer and endometrial cancer that is mismatch repair deficient and in combination with Imjudo in unresectable hepatocellular carcinoma in some countries.\nJ&J Seeks FDA Approval for Tremfya for Pediatric Use\nJ&J filed two supplemental biologics license applications (sBLAs) seeking approval of Tremfya in pediatric patients 6 years and older with moderate-to-severe plaque psoriasis and for children 5 years of age and older with active juvenile psoriatic arthritis. Tremfya, an IL-23 inhibitor, is already approved to treat certain adult patients with plaque psoriasis and active psoriatic arthritis in several countries, including the United States and the EU. Tremfya is also approved to treat moderately to severely active ulcerative colitis while it is under review in the EU for the same. Tremfya is under review in the United States and EU for the other inflammatory bowel disease condition, Crohn’s disease.\nFDA Accepts Roche’s Columvi sBLA for Aggressive Lymphoma\nThe FDA accepted for review Roche’s sBLA seeking expanded use of Columvi (glofitamab) in combination with chemotherapy for second-line relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). A final decision from the regulatory body is expected on July 20, 2025. The sBLA was based on data from the phase III STARGLO study. Roche is also seeking approval for similar use of Columvi in the EU and some other countries.\nColumvi is already approved in the United States, EU and several other countries for third-line R/R DLBCL.\nThe NYSE ARCA Pharmaceutical Index rose 0.5% in the past five trading sessions.\n\nLarge Cap Pharmaceuticals Industry 5YR % Return\n\nLarge Cap Pharmaceuticals Industry 5YR % Return\n\nHere’s how the eight major stocks performed in the previous five trading sessions.\nImage Source: Zacks Investment Research\nIn the last five trading sessions, Pfizer rose the most (1.5%), while Merck declined the most (1.4%).\nIn the past six months, while AbbVie rose the most (4.0%), Novo Nordisk declined the most (23.8%).\n(See the last pharma stock roundup here: Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success)\nWhat's Next in the Pharma World?\nWatch this space for regular pipeline and regulatory updates next week.\nAstraZeneca, Lilly, Merck, J&J and Roche have a Zacks Rank #3 (Hold) each. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAstraZeneca PLC (AZN) : Free Stock Analysis Report\nRoche Holding AG (RHHBY) : Free Stock Analysis Report\nJohnson & Johnson (JNJ) : Free Stock Analysis Report\nMerck & Co., Inc. (MRK) : Free Stock Analysis Report\nEli Lilly and Company (LLY) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489231752"}